| Literature DB >> 35214084 |
Guan-Rong Chen1, Mei-Ling Chang2, Shang-Tzen Chang1, Yu-Tung Ho1, Hui-Ting Chang1.
Abstract
The objective of the present study is to evaluate the cytotoxicity of Taiwania cryptomerioides essential oil and its phytochemical on the Hep G2 cell line (human hepatocellular carcinoma). Bark essential oil has significant cytotoxicity to Hep G2 cells, and S3 fraction is the most active fraction in cytotoxicity to Hep G2 cells among the six fractions. The diterpenoid quinone, 6,7-dehydroroyleanone, was isolated from the active S3 fraction by bioassay-guided isolation. 6,7-Dehydroroyleanone exhibited significant cytotoxicity in Hep G2 cells, and the efficacy of 6,7-dehydroroyleanone was better than the positive control, etoposide. Apoptosis analysis of Hep G2 cells with different treatments was characterized via flow cytometry to confirm the cell death situation. Etoposide and 6,7-dehydroroyleanone could induce the apoptosis in Hep G2 cells using flow cytometric assay. Results revealed 6,7-dehydroroyleanone from T. cryptomerioides bark essential oil can be a potential phytochemical to develop the anticancer chemotherapeutic agent for the treatment of the human hepatocellular carcinoma.Entities:
Keywords: Taiwania cryptomerioides; apoptosis; cytotoxicity; hep g2 cell line; human hepatocellular carcinoma
Year: 2022 PMID: 35214084 PMCID: PMC8880271 DOI: 10.3390/pharmaceutics14020351
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Differentiation of four cell populations by double immunocytochemistry labeling.
Cytotoxicity of bark essential oil and active fractions against Hep G2 cells.
| Specimen | Concentration | Cytotoxicity * | IC50 * |
|---|---|---|---|
| Bark oil | 12.5 | 10.23 ± 0.98 | 54.31 ± 0.60 a |
| 25 | 22.20 ± 0.10 | ||
| 50 | 49.47 ± 0.17 | ||
| 100 | 77.80 ± 0.17 | ||
| S2 fraction | 12.5 | 18.81 ± 0.90 | 32.22 ± 4.84 b |
| 25 | 26.43 ± 9.70 | ||
| 50 | 84.44 ± 1.75 | ||
| 100 | 90.62 ± 0.33 | ||
| S3 fraction | 12.5 | 44.37 ± 4.50 | 21.17 ± 1.09 c |
| 25 | 55.98 ± 3.57 | ||
| 50 | 82.61 ± 0.70 | ||
| 100 | 93.38 ± 0.23 |
Results are mean ± SD; *: 24 h of treatment; IC50 value: half maximal inhibitory concentration. Different letters (a–c) in the Table indicate significantly different at the level of p < 0.05 according to Scheffe’s test.
Figure 22D NMR spectra of 6,7-dehydroroyleanone. (a) HMQC; (b) HMBC; (c) COSY; (d) NOESY.
Figure 3Chemical and molecular structures of 6,7-dehydroroyleanone. (a) Chemical structure; (b) ORTEP diagram of the molecular structure.
Cytotoxicity of bark essential oil and 6,7-dehydroroyleanone against Hep G2 cells.
| Time | Specimen | IC50 | IC50 |
|---|---|---|---|
| 24 | Bark essential oil | 54.31 ± 0.60 b | - |
| 6,7-Dehydroroyleanone | 10.28 ± 0.18 d | 32.74 ± 0.57 C | |
| Etoposide * | 76.89 ± 0.34 a | 130.64 ± 0.58 A | |
| 48 | Bark essential oil | 30.27 ± 1.11 c | - |
| 6,7-Dehydroroyleanone | 5.22 ± 0.09 e | 16.62 ± 0.29 D | |
| Etoposide * | 29.68 ± 1.18 c | 50.43 ± 2.01 B |
Results are mean ± SD. *: Positive control. IC50 value: half maximal inhibitory concentration. Different letters (a–e; A–D) in the Table indicate significant difference at the level of p < 0.05 according to Scheffe’s test.
Figure 4Apoptosis analysis by Annexin V/PI flow cytometry of treated Hep G2 cells. (a) Control, 4 h; (b) etoposide, 50 µg/mL, 4 h; (c) S3a, 25 µg/mL, 4 h; (d) control, 24 h; (e) etoposide, 50 µg/mL, 24 h; (f) S3a, 25 µg/mL, 24 h; (g) control, 48 h; (h) etoposide, 50 µg/mL, 48 h; (i) S3a, 25 µg/mL, 48 h. S3a: 6,7-dehydroroyleanone.
Figure 5Etoposide and 6,7-dehydroroyleanone induced apoptosis in Hep G2 cells. (a) alive cells; (b) apoptotic cells. Etoposide, 50 µg/mL; S3a: 6,7-dehydroroyleanone, 25 µg/mL.